SuperworthNeuronetics EPS STIM
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$0.44
- Latest quarter, Q2 FY26
- −$0.05
- Fiscal year 2025
- −$0.59
Neuronetics' earnings per share was −$0.44 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.05.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.59 | n/a |
| FY2024 | −$1.38 | n/a |
| FY2023 | −$1.06 | n/a |
| FY2022 | −$1.38 | n/a |
| FY2021 | −$1.20 | n/a |
| FY2020 | −$1.46 | n/a |
| FY2019 | −$1.59 | n/a |
| FY2018 | −$55.67 | n/a |
| FY2017 | −$86.30 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.05 | n/a | −$0.44 | |
| Q1 FY26 | −$0.16 | n/a | −$0.54 | |
| Q4 FY25 | −$0.10 | n/a | −$0.59 | |
| Q3 FY25 | −$0.13 | n/a | −$0.83 | |
| Q2 FY25 | −$0.15 | n/a | −$1.14 | |
| Q1 FY25 | −$0.21 | n/a | −$1.32 | |
| Q4 FY24 | −$0.34 | n/a | −$1.38 | |
| Q3 FY24 | −$0.44 | n/a | −$1.22 | |
| Q2 FY24 | −$0.33 | n/a | −$1.11 | |
| Q1 FY24 | −$0.27 | n/a | −$0.95 | |
| Q4 FY23 | −$0.18 | n/a | −$1.06 | |
| Q3 FY23 | −$0.33 | n/a | −$1.18 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Neuronetics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| STIMNeuronetics | −$0.44 | |
| PDEXPro DEX | $4.11 | +52% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| MDXGMimedx | $0.04 | −81% a year |
| NEPHNephros | $0.16 | +33% a year |
| MOVMovado | $1.80 | +137% a year |
| Peer median | $1.27 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Neuronetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.